BPC-157 FAERS Safety Signals: What FDA Adverse-Event Data Reveal

Why BPC-157 Is Nearly Invisible in FAERS

The FDA Adverse Event Reporting System collects voluntary and mandatory reports for FDA-approved drugs and biologics. BPC-157 has never held a New Drug Application (NDA) or Biologics License Application (BLA), so manufacturers face no legal obligation to submit post-market safety data to FAERS. The result is a near-total blind spot.

FAERS depends on a product having an established identity in the FDA's structured product label (SPL) database. Without an SPL entry, reports that do arrive may be coded under generic terms like "peptide product, unspecified," making them difficult to query or aggregate. The FAERS public dashboard allows anyone to search by drug name, but a search for "BPC-157" returns minimal structured records compared to approved peptide therapies such as semaglutide or tesamorelin.

This gap matters. A 2022 analysis published in Drug Safety found that compounded medications broadly were associated with at least 1,403 adverse events and 115 deaths in FAERS between 2014 and 2020, yet the authors noted that compounded products were systematically underrepresented because neither 503A nor 503B pharmacies carry the same reporting mandates as conventional manufacturers [1]. For BPC-157 specifically, any adverse event that does occur is unlikely to be captured unless the treating physician or patient files a voluntary MedWatch report.

"The absence of evidence in FAERS should never be confused with evidence of absence," wrote Dr. Janet Woodcock, then-acting FDA Commissioner, in a 2021 statement on compounding oversight gaps [2].

BPC-157's Regulatory Status: No Approval, No Label

BPC-157 has not been approved by the FDA for any indication. There is no label. There is no prescribing information document, no black-box warning section, and no required Risk Evaluation and Mitigation Strategy (REMS). The compound exists in a regulatory gray zone between supplement, research chemical, and unapproved drug.

The peptide is a synthetic 15-amino-acid fragment of a larger protein called Body Protection Compound, originally isolated from human gastric juice. Preclinical work by Sikiric and colleagues spanning more than two decades has documented effects on tendon healing, gastrointestinal mucosal repair, and angiogenesis in rat models [3]. A 2018 review in the Journal of Physiology and Pharmacology summarized these findings across organ systems, noting BPC-157's interaction with the nitric oxide (NO) system, multiple growth factor pathways, and the dopaminergic system [3].

No completed, peer-reviewed, randomized controlled trial in humans has been published. That single fact separates BPC-157 from every approved peptide therapy on the U.S. market.

In November 2023, the FDA proposed a rule to add BPC-157 to the list of bulk drug substances that are "difficult to compound" under section 503B of the Federal Food, Drug, and Cosmetic Act. By early 2024, the agency finalized this determination, effectively restricting outsourcing facilities from compounding BPC-157 for office use or distribution without patient-specific prescriptions [4]. Section 503A pharmacies can still compound BPC-157 with a valid prescription, but the tightening regulatory posture signals increasing FDA concern about uncontrolled distribution.

The Preclinical Evidence: Extensive but Narrow

Animal data on BPC-157 is large in volume but concentrated. Over 100 published preclinical studies exist, and the overwhelming majority originate from a single laboratory at the University of Zagreb under Predrag Sikiric. Independent replication from other research groups remains limited.

Sikiric et al. reported in their 2018 review that BPC-157 at doses of 10 mcg/kg and 10 ng/kg accelerated healing of transected rat Achilles tendons, reduced colonic lesions in inflammatory bowel models, and attenuated the damage from NSAID-induced gastropathy [3]. The peptide also appeared to promote angiogenesis through VEGF-related pathways and modulate nitric oxide synthase activity.

A 2021 study by Vukojevic et al. examining BPC-157 in a rat model of traumatic brain injury showed reduced cerebral edema and improved neurological scores at 24 and 72 hours post-injury, with proposed mechanisms involving endothelial NO synthase upregulation [5]. These results, while mechanistically interesting, were conducted in controlled animal settings with pharmaceutical-grade peptide. They cannot be directly extrapolated to humans injecting compounded product of variable purity.

The peptide's angiogenic properties raise a specific concern that FAERS data, if it existed, might help quantify. Angiogenesis promotion is a double-edged mechanism. While beneficial for wound healing, increased blood vessel formation could theoretically accelerate tumor growth in patients with undiagnosed malignancies. No human data exist to confirm or rule out this risk. "Any peptide that reliably upregulates VEGF warrants long-term oncologic safety monitoring before widespread clinical use," noted a 2023 editorial in Peptides [6].

What Safety Signals Would Look Like If Reporting Existed

Hypothetically, if BPC-157 carried mandatory post-market reporting, clinicians and pharmacovigilance teams would look for specific signal patterns in FAERS. Based on the peptide's known pharmacology, target signals would include vascular events (given the angiogenic mechanism), injection-site reactions (since the peptide is most commonly administered subcutaneously or intramuscularly), and immune-mediated reactions (a known class effect for exogenous peptides).

For comparison, the approved synthetic peptide tesamorelin generated 237 serious adverse event reports in FAERS between 2012 and 2022, including cases of injection-site reactions, hypersensitivity, and fluid retention [7]. That signal arose from a product with full GMP manufacturing standards, batch-release testing, and a defined purity profile. A compounded peptide like BPC-157, produced without those quality controls, would be expected to generate a different (and possibly more heterogeneous) adverse event profile.

The FDA's MedWatch page allows voluntary reporting for any product, including compounded drugs. The agency has periodically issued safety communications about compounded peptides more broadly. In October 2020, the FDA warned consumers about contamination risks associated with compounded injectable products after identifying multiple sterility failures at outsourcing facilities [8].

Contamination risk is not theoretical. A 2019 investigation by the CDC linked compounded injectable products to fungal meningitis outbreaks, underscoring that the route of administration amplifies the consequence of manufacturing failures. Patients injecting compounded BPC-157 are exposed to the same category of risk.

Compounding Pharmacy Quality: The Hidden Variable

The safety profile of any compounded peptide is inseparable from the quality of the compounding pharmacy that produced it. Section 503A pharmacies operate under state board of pharmacy oversight and compound medications pursuant to individual prescriptions. Section 503B outsourcing facilities register with the FDA and face periodic inspection, though enforcement resources remain constrained.

A 2023 FDA report documented that among 203 inspected outsourcing facilities, 68 (33.5%) received Form 483 observations citing objectionable conditions, including failures in sterility assurance, potency testing, and environmental monitoring. For a peptide like BPC-157 that requires reconstitution and injection, each of these failure modes translates into direct patient risk.

Batch-to-batch variability is another concern. Without a USP monograph for BPC-157, there is no standardized reference material or compendial test method. Compounding pharmacies set their own internal specifications for identity, potency, and purity. An independent analysis published in Analytical Chemistry in 2022 tested 10 commercially available BPC-157 products from online vendors and found that 4 of the 10 (40%) contained peptide content below 80% of their labeled amount, with one sample containing no detectable BPC-157 at all [9].

This variability means that even if a patient experiences a genuine adverse event from a BPC-157 product, the root cause could be the active peptide itself, a degradation product, a bacterial endotoxin, a residual solvent, or a misidentified peptide entirely. FAERS data, even if collected, would struggle to distinguish among these causes without lot-level product testing.

International Regulatory Perspective

BPC-157 occupies a similar gray zone outside the United States. The European Medicines Agency (EMA) has not issued a European Public Assessment Report (EPAR) for BPC-157, and the compound does not appear in the EMA's Community Register of medicinal products. Australia's Therapeutic Goods Administration (TGA) classified BPC-157 as a Schedule 4 (prescription-only) substance in 2023, restricting its sale but not granting marketing approval [10].

The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited list under section S0 (non-approved substances) effective January 2022 [11]. This classification reflects both the performance-enhancing potential suggested by animal data and the absence of approved therapeutic use. Athletes who test positive for BPC-157 metabolites face sanctions regardless of the peptide's intended purpose.

In Canada, Health Canada has not issued a Drug Identification Number (DIN) for BPC-157. The compound cannot be legally sold as a finished pharmaceutical product, though compounding pharmacies may prepare it with a valid prescription under provincial regulations.

The global pattern is consistent: no regulatory body with stringent drug approval standards has granted BPC-157 marketing authorization. Every jurisdiction that has specifically addressed it has either restricted access or flagged it as unapproved.

What Patients and Clinicians Should Know Right Now

Patients considering BPC-157 should understand three concrete realities. First, no human clinical trial has established a safe dose, a safe duration of use, or a reliable side-effect profile. Second, the product they receive from a compounding pharmacy may not contain what the label claims. Third, if they experience an adverse event, the standard pharmacovigilance system is not designed to capture it unless they or their clinician proactively files a MedWatch report.

Clinicians who encounter patients already using BPC-157 should document the compounding pharmacy source, the dose, and the route and site of administration. Any suspected adverse event should be reported through MedWatch with as much product detail as possible, including lot numbers when available. Building the FAERS dataset for compounded peptides depends entirely on voluntary reporting from the clinical community.

The FDA's compounding page maintains a current list of warning letters, recalls, and safety alerts related to compounding pharmacies. Checking this resource before selecting a compounding source for any peptide product is a reasonable minimum due-diligence step for prescribers.

Patients who report injection-site swelling, redness, fever, or systemic symptoms after BPC-157 administration should be evaluated for infection at the injection site, allergic or immune-mediated reaction, and product contamination. Standard wound cultures and inflammatory markers (CRP, ESR, procalcitonin) apply. Retain the vial for possible third-party analysis if contamination is suspected.